WO2001028544A2 - Dialysis solution including polyglycol osmotic agent - Google Patents
Dialysis solution including polyglycol osmotic agent Download PDFInfo
- Publication number
- WO2001028544A2 WO2001028544A2 PCT/US2000/028523 US0028523W WO0128544A2 WO 2001028544 A2 WO2001028544 A2 WO 2001028544A2 US 0028523 W US0028523 W US 0028523W WO 0128544 A2 WO0128544 A2 WO 0128544A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dialysis solution
- osmotic agent
- dialysis
- molecular weight
- free radical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Definitions
- Renal dialysis involves the diffusion of water and waste products, (e.g., urea, excess salts, toxins, impurities, etc.) from a patient's blood, through a semipermeable membrane, and into a dialysis solution. Dialysis most commonly takes one of two forms: hemodialysis involves contacting a portion of the patient's blood with a synthetic semipermeable membrane wherein water and waste products diffuse from the blood through the membrane and into a dialysis solution. The "cleansed" blood is then returned to the patient. Peritoneal dialysis involves infusing a dialysis solution into the patient's peritoneum.
- waste products e.g., urea, excess salts, toxins, impurities, etc.
- the peritoneum comprises a cavity surrounded by blood vessels and capillary beds allowing it to act as a natural semipermeable membrane. Water and waste products diffuse from the blood, through the peritoneum and into the dialysis solution, which is subsequently removed from the patient.
- Dialysis solutions are typically aqueous solutions including electrolytes, bicarbonate buffer, and an osmotic agent, i.e., a constituent utilized to create an osmotic gradient between a patient's blood and the dialysis solution.
- osmotic agents include a carbohydrate containing osmotic agent such as glucose and dextrose.
- U.S. Patent 4,886,789 describes mixtures containing at least 15 weight percent of glucose polymers having a degree of polymerization greater than 12.
- Glucose polymers of this type can be relatively expensive to synthesize and are susceptible to degradation when subjected to gamma sterilization.
- U.S. Patent 4,339,433 discloses a variety of dialysis solutions including non- carbohydrate osmotic agents. Unfortunately, these agents can be susceptible to degradation when subjected to gamma sterilization. Moreover, these agents are relatively expensive to produce.
- This invention relates to a dialysis solution and method for its use wherein the solution includes an osmotic agent comprising a water soluble polyglycol having a molecular weight (number average molecular weight) from 500 to 20,000 daltons.
- Selection of a specific polyglycol species may be at least partially based upon the pore size of the semipermeable membrane used in the dialysis treatment.
- the pore size of such membranes tends to be distribution of sizes rather than a uniform size. Nonetheless, such membranes are commonly characterized in terms of a "molecular weight cut-off' value. Materials having a molecular weight greater than the specified molecular weight cut-off of a membrane are substantially blocked, or incapable of passing through the membrane.
- the subject polyglycols include polyethylene glycol having a molecular weight from: 3,000 to 5,000 for use in peritoneal dialysis and from 6,000 to 10,000 in hemodialysis utilizing currently marketed ultrafiltration membranes having a molecular weight cutoff of about 5,000.
- Lower molecular weight polyglycols e.g., from 1,000 to 3,000, can be used in hemodialysis utilizing semipermeable membranes having very small molecular weight cutoffs (e.g., 500 to 1,000).
- the subject osmotic agents are substantially impermeable through the peritoneum and the semipermeable membranes typically used in hemodialysis. Consequently, relatively high concentrations of the subject osmotic agent can be safely used, resulting in a significant reduction in the total volume of dialysis solution required and the time required for dialysis treatment. Moreover, many polyglycols suitable for use in the present invention are produced on a large commercial scale and are relatively inexpensive. For example, pharmaceutical grade polyethylene glycol having a range of suitable molecular weights are available.
- polyethylene glycol e.g., polyethylene oxide
- Species of the subject polyglycols are well known for their biocompatibility and safety in medical uses, e.g., ophthalmic solutions, wound dressings, drug delivery, mucoadhesives, etc.
- polyethylene glycol e.g., polyethylene oxide
- free radical scavengers in the dialysis solution.
- sterilization of the solution using gamma radiation can be accomplished with minimal damage to solution components while maintaining a physiological pH.
- a free radical scavenger is human serum albumin.
- the subject free radical scavengers can be utilized independently from the osmotic agents disclosed herein.
- a polyglycol material having functional groups capable of forming associations with waste products (e.g., urea) removed from the blood during dialysis.
- the dialysis solution of the present invention includes a physiologically acceptable aqueous solution including a water-soluble polyglycol.
- the solution has a physiologically acceptable pH and preferably includes physiologically acceptable salts, buffers and other constituents, as is well known in the art.
- U.S. Patent 4,308,255 to Raj et al. describes dialysis solutions including physiologically acceptable quantities of sodium, chloride, potassium, bicarbonate, calcium, and magnesium.
- the molecular weight of the subject polyglycol must be sufficiently high to prevent significant quantities of polyglycol from passing through the semipermeable membrane during dialysis treatment. However, the molecular weight must be low enough such that reasonable quantities of the polyglycol provide a sufficient osmotic driving force for water and waste products to pass through a semipermeable membrane and into the dialysis solution.
- the preferred molecular weight range for the subject polyglycols is from 500 to 20,000, depending at least partially upon the molecular weight cut-off of the membrane being utilized for dialysis. For most appUcations, molecular weights from about 3,000 to 5,000 are particularly preferred. It should be understood that higher molecular weight polyglycols may be used in combination with those falling within the specified range.
- polyglycols is intended to include water soluble polymers including repeating units represented by: -(CH 2 CH 2 O)-.
- examples of such polyglycols include polyethylene glycol, also known as polyether glycol or polyoxyethylene. Preferred species included can be described as having the following repeating units: -(CH 2 CH 2 O) n - wherein n is an integer resulting in a molecular weight within the range described above.
- the subject polyglycols may further include branched polymers including multiple branches of repeating units represented by -(CH 2 CH 2 O)-.
- Such polymers can be produced by polymerizing, grafting or otherwise reacting individual ethylene oxide groups, or polymers or pre-polymers thereof with polyhydric alcohols (e.g., glycerol. carbohydrates and the like), polyhydroxy aldehydes, polyhydroxy ketones, etc., such as by way of a condensation reaction via a pendant hydroxyl groups of glycerol, ribose etc.
- polyhydric alcohols e.g., glycerol. carbohydrates and the like
- polyhydroxy aldehydes e.g., polyhydroxy ketones, etc.
- other compounds falling within the subject definition of polyglycols can be formed through use of polymers based on the monomer epichlorohydrin wherein the organic chloride groups of the resulting polymer are derivitized with amines to form quaternary amine groups.
- branched polymers may offer added steric hinderance such that relatively smaller molecular weight species will not pass through the pores of the semipermeable membrane used during dialysis.
- the subject polyglycols may include terminal hydroxyl, aldehydes, carboxylic acid groups and/or other functional groups that are capable of forming association with blood borne waste products (e.g., urea). National formulary (NF) grades of these materials are preferred.
- NF National formulary
- the subject polyglycols may be used in combination with other known osmotic agents glucose, dextrose, and other carbohydrate containing osmotic agents. Moreover, the subject polyglycols may be used in combination with the osmotic agents described in U.S. Patents 5,869,444; 4,761,237; 4,976,683; 4,604,379; 4,959,175; 4,339,433; and 4,886,789. However, the subject polyglycols preferably do not include "surfactants", (e.g., polysorbate); that is, they do not include significant hydrophilic portions which result in water insolubility.
- surfactants e.g., polysorbate
- Peritoneal dialysis solutions of the present invention typically include from 0.05 mole to 1.0 mole of the polyglycol per cycle of treatment. In the case where 1 or 2 liters of dialysate are used for one cycle of peritoneal dialysis, 100 to 10,000 grams of polyglycol per liter of solution are typically used, depending upon the specific application, the presence of other osmotic agents, and the molecular weight of the polyglycol. More typically, a dialysis cycle would use from 0.1 to 0.5 mole of polyglycol wherein the dialysis solution includes about 300 grams of polyglycol per liter of solution.
- Hemodialysis solutions of the present solution typically include from 0.001 mole to
- the subject dialysis solution preferably includes a free radical scavenger to reduce complications caused by the production of degradation products from gamma sterilization.
- free radical scavengers include: salicylic acid, Fe(II) phenantholine, dihydroxybenzoic acid (gentisic acid), human serum albumin, glutathione, and cysteine.
- the subject polyglycols are less susceptible to forming detrimental degradation products when exposed to sterilization conditions than conventional glucose solutions.
- comparable dialysis solutions were prepared utilizing different osmotic agents: glucose and polyethylene glycol 3350 (approximate molecular weight).
- the solutions were subjected to common sterilization conditions, i.e., autoclave and gamma radiation (with Cobalt 60). After sterilization, the pH of each solution was measured. The pH of the glucose containing solutions had dropped significantly; whereas the pH of polyethylene glycol containing solutions had remained relatively stable.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00968956A EP1223985B1 (en) | 1999-10-15 | 2000-10-13 | Dialysis solution including polyglycol osmotic agent |
DE60024479T DE60024479T2 (en) | 1999-10-15 | 2000-10-13 | DIALYSIS SOLUTION CONTAINING POLYGLYCOL AS OSMOTIC AGENT |
CA002382864A CA2382864A1 (en) | 1999-10-15 | 2000-10-13 | Dialysis solution including polyglycol osmotic agent |
AU78795/00A AU7879500A (en) | 1999-10-15 | 2000-10-13 | Dialysis solution including polyglycol osmotic agent |
JP2001531374A JP2003512322A (en) | 1999-10-15 | 2000-10-13 | Dialysis solution containing polyglycol penetrant |
AT00968956T ATE311203T1 (en) | 1999-10-15 | 2000-10-13 | DIALYSE SOLUTION CONTAINING POLYGLYCOL AS AN OSMOTIC AGENT |
BR0014820-2A BR0014820A (en) | 1999-10-15 | 2000-10-13 | Dialysis solution including polyglycol osmotic agent, and its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15981099P | 1999-10-15 | 1999-10-15 | |
US60/159,810 | 1999-10-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001028544A2 true WO2001028544A2 (en) | 2001-04-26 |
WO2001028544A3 WO2001028544A3 (en) | 2001-11-29 |
Family
ID=22574137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/028523 WO2001028544A2 (en) | 1999-10-15 | 2000-10-13 | Dialysis solution including polyglycol osmotic agent |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1223985B1 (en) |
JP (1) | JP2003512322A (en) |
AT (1) | ATE311203T1 (en) |
AU (1) | AU7879500A (en) |
BR (1) | BR0014820A (en) |
CA (1) | CA2382864A1 (en) |
DE (1) | DE60024479T2 (en) |
WO (1) | WO2001028544A2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053059B2 (en) | 2003-07-25 | 2006-05-30 | Baxter International Inc. | Dialysis solutions with reduced levels of glucose degradation products |
WO2007130848A2 (en) * | 2006-05-03 | 2007-11-15 | Warsaw Orthopedic, Inc | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
WO2007147590A3 (en) * | 2006-06-22 | 2008-03-13 | Gambro Inc | Solution and method to reduce, treat and/or prevent oxidative stress and cell activation |
ES2332636A1 (en) * | 2008-08-06 | 2010-02-09 | Universitat De Les Illes Balears | Composition of dialysis liquid comprising crystallisation inhibitor substances |
US8057458B2 (en) | 2006-10-30 | 2011-11-15 | Warsaw Orthopedic, Inc. | Method for treating facet pain |
US8153112B2 (en) | 2007-08-03 | 2012-04-10 | Warsaw Orthopedic, Inc. | Compositions and methods for treating cavity conditions |
US8840933B2 (en) | 2006-05-03 | 2014-09-23 | Warsaw Orthopedic, Inc. | Method of treating neuronal injury by administering magnesium chloride and PEG |
US8852566B2 (en) | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
US8858924B2 (en) | 2009-03-26 | 2014-10-14 | Warsaw Orthopedic, Inc. | Compositions and methods for treatment of hemorrhage |
US8956667B2 (en) | 2009-03-26 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods of identifying potential components for targeted drug delivery compositions |
US9078808B2 (en) | 2009-03-26 | 2015-07-14 | Warsaw Orthopedic, Inc. | Device to deliver magnesium in PEG formulation |
US9244060B2 (en) | 2009-03-26 | 2016-01-26 | Warsaw Orthopedic, Inc. | Site localization and methods for monitoring treatment of disturbed blood vessels |
US9597352B2 (en) | 2005-05-31 | 2017-03-21 | Warsaw Orthopedic, Inc. | Compositions and methods for treating pain |
US9675696B2 (en) | 2006-11-14 | 2017-06-13 | Warsaw Orthopedic, Inc. | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain |
US11160766B2 (en) | 2015-07-20 | 2021-11-02 | Opterion Health Ag | Peritoneal therapeutic fluid |
CN115624566A (en) * | 2022-12-22 | 2023-01-20 | 广东省人民医院 | Peritoneal dialysis solution and preparation method and application thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2421908A (en) * | 2004-12-23 | 2006-07-12 | Univ College London Hospitals | Medicament for treatment of inflammatory diseases |
US9919004B2 (en) | 2012-04-24 | 2018-03-20 | The University Of British Columbia | Polymer-based dialysate |
WO2015074139A1 (en) | 2013-11-21 | 2015-05-28 | University Of British Columbia | Polymer based transplant preservation solution |
JP6523614B2 (en) * | 2014-04-22 | 2019-06-05 | 日機装株式会社 | Dehydrator for used dialysate and dialysate regeneration system using the same |
WO2023099436A1 (en) * | 2021-12-01 | 2023-06-08 | Gambro Lundia Ab | New dialysis fluid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
WO1998017707A1 (en) * | 1996-10-23 | 1998-04-30 | The Dow Chemical Company | Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption |
-
2000
- 2000-10-13 AT AT00968956T patent/ATE311203T1/en not_active IP Right Cessation
- 2000-10-13 AU AU78795/00A patent/AU7879500A/en not_active Abandoned
- 2000-10-13 EP EP00968956A patent/EP1223985B1/en not_active Expired - Lifetime
- 2000-10-13 BR BR0014820-2A patent/BR0014820A/en not_active Application Discontinuation
- 2000-10-13 DE DE60024479T patent/DE60024479T2/en not_active Expired - Fee Related
- 2000-10-13 CA CA002382864A patent/CA2382864A1/en not_active Abandoned
- 2000-10-13 JP JP2001531374A patent/JP2003512322A/en active Pending
- 2000-10-13 WO PCT/US2000/028523 patent/WO2001028544A2/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
WO1998017707A1 (en) * | 1996-10-23 | 1998-04-30 | The Dow Chemical Company | Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption |
Non-Patent Citations (4)
Title |
---|
DAVANKOV V ET AL: "Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure" JOURNAL OF CHROMATOGRAPHY. BIOMEDICAL APPLICATIONS,NL,ELSEVIER, AMSTERDAM, vol. 739, no. 1, February 2000 (2000-02), pages 73-80, XP004190288 ISSN: 0378-4347 * |
FUJIMURA N ET AL: "Alteration in diaphragmatic contractility during septic peritonitis in rats: effect of polyethylene glycol -absorbed superoxide dismutase." CRITICAL CARE MEDICINE, (2000 JUL) 28 (7) 2406-14. , XP000997182 * |
FUJIMURA N ET AL: "Effect of free radical scavengers on diaphragmatic contractility in septic peritonitis." AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (2000 DEC) 162 (6) 2159-65. , XP000997217 * |
GALINANES M. ET AL: "PEG -SOD and myocardial protection: Studies in the blood- and crystalloid- perfused rabbit and rat hearts." CIRCULATION, (1992) 86/2 (672-682). , XP000997181 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053059B2 (en) | 2003-07-25 | 2006-05-30 | Baxter International Inc. | Dialysis solutions with reduced levels of glucose degradation products |
US9597352B2 (en) | 2005-05-31 | 2017-03-21 | Warsaw Orthopedic, Inc. | Compositions and methods for treating pain |
JP2009535416A (en) * | 2006-05-03 | 2009-10-01 | ウォーソー・オーソペディック・インコーポレーテッド | Compositions containing biomembrane sealing agents for the treatment of nerve damage and methods of use |
WO2007130848A2 (en) * | 2006-05-03 | 2007-11-15 | Warsaw Orthopedic, Inc | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
WO2007130848A3 (en) * | 2006-05-03 | 2008-01-24 | Warsaw Orthopedic Inc | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
US9717756B2 (en) | 2006-05-03 | 2017-08-01 | Warsaw Orthopedic, Inc. | Method of treating traumatic brain or spinal cord injury with biomembrane sealing agent and magnesium compounds |
US8945623B2 (en) | 2006-05-03 | 2015-02-03 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
US9950005B2 (en) | 2006-05-03 | 2018-04-24 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
AU2007248226B2 (en) * | 2006-05-03 | 2012-11-08 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
JP2014074061A (en) * | 2006-05-03 | 2014-04-24 | Warsaw Orthopaedic Inc | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
US8840933B2 (en) | 2006-05-03 | 2014-09-23 | Warsaw Orthopedic, Inc. | Method of treating neuronal injury by administering magnesium chloride and PEG |
WO2007147590A3 (en) * | 2006-06-22 | 2008-03-13 | Gambro Inc | Solution and method to reduce, treat and/or prevent oxidative stress and cell activation |
US8057458B2 (en) | 2006-10-30 | 2011-11-15 | Warsaw Orthopedic, Inc. | Method for treating facet pain |
US9675696B2 (en) | 2006-11-14 | 2017-06-13 | Warsaw Orthopedic, Inc. | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain |
US8153112B2 (en) | 2007-08-03 | 2012-04-10 | Warsaw Orthopedic, Inc. | Compositions and methods for treating cavity conditions |
ES2332636A1 (en) * | 2008-08-06 | 2010-02-09 | Universitat De Les Illes Balears | Composition of dialysis liquid comprising crystallisation inhibitor substances |
US8858924B2 (en) | 2009-03-26 | 2014-10-14 | Warsaw Orthopedic, Inc. | Compositions and methods for treatment of hemorrhage |
US9452183B2 (en) | 2009-03-26 | 2016-09-27 | Warsaw Orthopedic, Inc. | Compositions and methods for treatment of hemorrhage |
US9486478B2 (en) | 2009-03-26 | 2016-11-08 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
US9244060B2 (en) | 2009-03-26 | 2016-01-26 | Warsaw Orthopedic, Inc. | Site localization and methods for monitoring treatment of disturbed blood vessels |
US9078808B2 (en) | 2009-03-26 | 2015-07-14 | Warsaw Orthopedic, Inc. | Device to deliver magnesium in PEG formulation |
US8956667B2 (en) | 2009-03-26 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods of identifying potential components for targeted drug delivery compositions |
US8852566B2 (en) | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
US10883976B2 (en) | 2009-03-26 | 2021-01-05 | Warsaw Orthopedic, Inc. | Methods of identifying potential components for targeted drug delivery compositions |
US11160766B2 (en) | 2015-07-20 | 2021-11-02 | Opterion Health Ag | Peritoneal therapeutic fluid |
CN115624566A (en) * | 2022-12-22 | 2023-01-20 | 广东省人民医院 | Peritoneal dialysis solution and preparation method and application thereof |
CN115624566B (en) * | 2022-12-22 | 2023-03-10 | 广东省人民医院 | Peritoneal dialysis solution and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1223985B1 (en) | 2005-11-30 |
DE60024479T2 (en) | 2006-05-18 |
BR0014820A (en) | 2002-06-11 |
EP1223985A2 (en) | 2002-07-24 |
DE60024479D1 (en) | 2006-01-05 |
CA2382864A1 (en) | 2001-04-26 |
AU7879500A (en) | 2001-04-30 |
WO2001028544A3 (en) | 2001-11-29 |
JP2003512322A (en) | 2003-04-02 |
ATE311203T1 (en) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1223985B1 (en) | Dialysis solution including polyglycol osmotic agent | |
EP1585531B1 (en) | Biocompatible dialysis fluids containing icodextrins | |
CA2263379C (en) | Method for iron delivery to a patient by transfer from dialysate | |
EP0760689B1 (en) | Method of manufacturing and storing solutions | |
US11285173B2 (en) | Dialysis solution, formulated and stored in two parts, comprising phosphate | |
JP2008502722A (en) | Bicarbonate-based peritoneal dialysis solution | |
KR20150013161A (en) | Polymer-based dialysate | |
US20030202958A1 (en) | Dialysis solution including polyglycol osmotic agent | |
WO2007016377A2 (en) | Dialysis solution including water-soluble polyelectrolyte osmotic agent | |
AU2006200162A1 (en) | Dialysis solution including polyglycol osmotic agent | |
JPH1171273A (en) | Peritoneum dialysing fluid | |
JP4430500B2 (en) | Hydrogen carbonate ion-containing chemicals | |
Holmes | Peritoneal immune defense in continuous ambulatory peritoneal dialysis: clinical relevance and practical implications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000968956 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 78795/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2382864 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 531374 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000968956 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000968956 Country of ref document: EP |